Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-α-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats

Chemical Research in Toxicology

Volumn 9, Issue 2, 1996, Pages 457-465

  Miller, R Timothy ^a   Lau, Serrine S ^a   Monks, Terrence J ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; MEDA;

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 (GLUTATHION S YL) ALPHA METHYLDOPAMINE; ALPHA METHYLDOPAMINE; DOPAMINE; DRUG METABOLITE; GLUTATHIONE; NORADRENALIN; SEROTONIN; UNCLASSIFIED DRUG;

AGGRESSION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG UPTAKE; FOREFOOT; GLUTATHIONE METABOLISM; HYPERACTIVITY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; NEUROTOXICITY; NONHUMAN; NORADRENALIN RELEASE; NORADRENERGIC SYSTEM; PRESSOR RESPONSE; RAT; SEROTONINERGIC SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BRAIN; BRAIN CHEMISTRY; DEOXYEPINEPHRINE; DOPAMINE; GLUTATHIONE; INJECTIONS, INTRAVENTRICULAR; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN;

EID: 0029884986     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx9501546     Document Type: Article

References (56)

1. Baum, R M (1985) New variety of street drugs poses growing problem. Chem Eng. News 63, 7-16.
2. Peroutka, S. J. (1987) Incidence of recreational use of 3,4-methylenedioxymethamphetamine (MDMA, "ECSTACY") on an undergraduate campus N. Engl. J Med. 317, 1542-1543.
3. Shulgin, A. T. (1981) Hallucinogens. In Burger's Medicinal Chemistry (Wolff, M. E., Ed.) 4th ed., Part III, Wiley, New York.
4. Greer, G., and Strassman, R. J. (1985) Information on "ecstacy". Am. J. Psychiatry 142, 1391
5. Winstock, A. R (1991) Chronic paranoid psychosis after misuse of MDMA. Br. Med. J. 302, 1150-1151.
6. Fuller, R. W (1976) Pharmacology of p-chloroamphetamine and analogs. Psychopharmacol. Bull. 12, 55-57.
7. Ricaurte, G. A., Bryan, G., Strauss, L., Seiden, L., and Schuster, C. (1985) Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229, 986-988.
8. Ricaurte, G A., Martello, A. L., Katz, J L., and Martello, M. B. (1992) Lasting effects of 3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: Neurochemical observations. J. Pharmacol. Exp. Ther. 261, 616-622.
9. Axt, K. J., Mullen, C. A., and Molliver, M. E, (1992) Cytopathologic features indicative of 5-hydroxytryptamine axon degeneration are observed in rat brain after administration of D- and L-methylenedioxyamphetamine. In Neurotoxins and Neurodegenerative Disease, Ann. N. Y. Acad. Sci. 648, 245-247.
10. Berger, U. V., Gu, X. F , and Azmitia, E. C. (1992) The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur. J. Pharmacol 215, 153-160.
11. Hashimoto, K., Maeda, H., and Goromaru, T. (1992) Effects of benzylpiperazine derivatives on the neurotoxicity of 3,4-methylenedioxymethamphetamine in rat brain. Brain Res. 590, 341-344
12. Schmidt, C. J., Black, C. K., and Taylor, V L. (1991) L-Dopa potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats. Eur. J. Pharmacol 203, 41-49.
13. Ricaurte, G. A., Delanney, L. E., Irwin, I., and Langston, J W. (1988) Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res. 446, 165-168.
14. Schmidt, C J., And Taylor, V. L. (1988) Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons. Eur. J. Pharmacol. 156, 121-131.
15. Logan, B. J., Laverty, R., Sanderson, W. D., and Yee, Y. B. (1988) Differences between rats and mice in MDMA (methylenedioxymethamphetamine) neurotoxicity. Eur J. Pharmacol. 152, 227-234.
16. Johnson, M., Elayan, I., Hanson, G. R., Foltz, R. L., Gibb, J. W , and Lim, H.K. (1992) Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxyamphetamine, on central serotonergic and dopaminergic systems. J. Pharmacol. Exp. Ther. 261, 447-453.
17. Zhao, Z., Castagnoli, N., Jr., Ricaurte, G. A., Steele, T., and Martello, M. (1992) Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methyl-amino)-1-[3,4-(methylenedioxy)phenyl]propane[(methylenedioxy)- methamphetamine]. Chem. Res Toxicol. 5, 89-94.
18. Lin, L., Kumagai, Y., and Cho, A. K. (1992) Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. Chem. Res. Toxicol 5, 401-406.
19. Kumagai, Y., Wickham, K. Schmitz, D. A., and Cho, A. K (1991) Metabolism of methylenedioxyphenyl compounds by rabbit liver preparations. Biochem. Pharmacol. 42, 1061-106.
20. Midha, K. K., Hubbard, J. W., Bailey, K., and Cooper, J. K. (1978) α-Methyldopamine, a key intermediate in the metabolic disposition of 3,4-methylenedioxyamphetamine in vivo in dog and monkey. Drug Metab. Dispos 6, 623-630.
21. Lim, H. K., and Foltz, R. L. (1988) In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. Chem. Res. Toxicol. 1, 370-378.
22. Hiramatsu, M., Kumagai, Y., Unger, S. E., and Cho, A. K (1990) Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J. Pharmacol. Exp. Ther. 254, 521-527.
23. Kumagai, Y., Lin, L., Schmitz, D. A., and Cho, A. K. (1991) Hydroxyl radical mediated demethylenation of (methylenedioxy)-phenyl compounds. Chem. Res. Toxicol. 4, 330-334.
24. McCann, U. D., and Ricaurte, G. A. (1991) Major metabolites of (±)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons. Brain Res. 545, 279-282
25. Patel, N., Kumagai, Y., Unger, S. E., and Cho, A. K. (1991) Transformation of dopamine and α-methyldopamine by NG-108-15 cells: formation of thiol adducts. Chem. Res. Toxicol. 4, 421-426.
26. Monks, T. J. and Lau, S S. (1994) Glutathione conjugation as a mechanism for the transport of reactive metabolites. In Advances in Pharmacology. Vol. 27: Conjugation-Dependent Carcinogenicity and Toxicology of Foreign Compounds (Anders, M. W , and Dekant, W., Eds.) pp 183-210, Academic Press, New York
27. Wefers, H . and Sies, H. (1983) Hepatic low-level chemiluminesence during redox cycling of menadione and the menadioneglutathione conjugate: Relation to glutathione and NAD(P)H, quinone reductase (DT diaphorase) activity. Arch Biochem. Biophys. 224, 568-578.
28. Monks, T. J , Highet, R. J., and Lau, S. S. (1988) 2-Bromo-(diglutathion-S-yl)hydroquinone nephrotoxicity: Physiological, biochemical and electrochemical determinants. Mol Pharmacol. 34, 492-500.
29. Miller, R. T., Lau, S. S., and Monks, T. J. (1995) Metabolism of 5-(glutathion-S-yl)-α-methyldopamine following intracerebroventricular administration to male Sprague Dawley rats. Chem. Res. Toxicol. 8, 634-640.
30. 3H-water as diffusable internal standards for measuring brain extraction of radio-labeled substances following carotid injection. Brain Res 113, 219-224.
31. 13O-labeled water. Am. J. Physiol. 230, 543-552.
32. Schmidt, C. J., Levin, J A , and Lovenberg, W. (1987) In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem. Pharmacol. 36, 747-755.
33. Fitzgerald, J. L , and Reid, J. J (1990) Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur. J. Pharmacol. 191, 217-220.
34. Kuczenski, R., and Segal, D. S. (1994) Neurochemistry of Amphetamine. In Amphetamine and its Analogs; Psychopharmacology, Toxicology, and Abuse (Cho, A. K., and Segal, D. S., Eds.) pp 81-113, Academic Press, San Diego, CA.
35. Marquardt, G. M., Distefano, V., and Ling, L. L. (1978) Pharmacological effects of (±), (S)-, and (R)-MDA. In The Psychopharmacology of Hallucinogens (Stillman, R. C., and Willette, R. E., Eds.) pp 85-104, Pergamon Press, New York.
36. Grahme-Smith, D. G. (1971) Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J. Neurochem. 18, 1053-1066.
37. Stone, D. M., Johnson, M., Hanson, G. R., and Gibb, J. W. (1988) Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 247, 79-87.
38. Brodkin, J., Malyala, A., and Nash, J. F. (1993) Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol. Biochem. Behav. 45 (3), 647-653.
39. Fujimori, M., and Himwich, H. E. (1969) Electroencephalographic analysis of amphetamine and its methoxy derivatives with reference to their sites of EEG alerting in the rabbit brain. Int. J. Neuropharmacol. 8, 601-613.
40. 3H]-glutathione in rat central and peripheral tissues. Neurochem. Int. 13, 493-497.
41. Zangerle L., Cuenod, M., Winterhalter, K. H., and Do, K. Q. (1990) Screening of thiol compounds: Depolarization-induced release of glutathione and cysteine from rat brain slices. J. Neurochem. 59, 181-189.
42. Leslie, S. W., Brown, L. M., Trent, R. D., Lee, Y.-H., Morris, J. L., Jones, T. W., Randall, P. K., Lau, S. S., and Monks, T. J. (1992) Stimulation of N-methyl-D-aspartate receptor-mediated calcium entry into dissociated neurons by reduced and oxidized glutathione. Mol. Pharmacol. 41, 308-314.
43. Liu, Y. F., and Quirion, R. (1992) Modulatory role of glutathione on μ-opioid, substance P/neurokinin 1, and kainic acid receptor binding sites. J. Neurochem. 59, 1024-1032.
44. Kubo, E., Horiuchi, T., Nakamura, A., and Shiomi, H. (1992) Potent antinociceptive effects of centrally administered glutathione and glutathione-disulfide in mice. Jpn. J. Pharmacol. 58, Suppl. 1, 311.
45. Guo, N., Mcintosh, C., and Shaw, C. (1992) Glutathione; new candidate neuropeptide in the central nervous system. Neuroscience 4, 835-842.
46. Pileblad, E., Magnusson, T., and Fornstedt, B. (1989) Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxy-dopamine in rat striatum. J. Neurochem. 52, 978-980.
47. Strupp, M., Quasthoff, N., Mitrovic, N., and Grafe, P. (1992) Glutathione accelerates sodium channel inactivation in excised rat axonal membrane patches. Eur. J Physiol. (Pflugers Arch.), 421, 283-285.
48. Wolff, J. E. A., Belloni-Olivi, L., Bressler, J. P., and Goldstein, G. W. (1992) γ-Glutamyl transpeptidase activity in brain microvessels exhibits regional heterogeneity. J. Neurochem. 58, 909-915.
49. Kannan, R., Kuhlenkamp, J. F., Jeandidier, E., Trinh, H., Ookhtens, M., and Kaplowitz, N. (1990) Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. J. Clin. Invest. 85, 2009-2013.
50. Cornford, E. M., Braun, L. D., Crane, P D., and Oldendorf, W. H. (1978) Blood-brain barrier restriction of peptides and the low uptake of enkephalins. Endocrinology 103, 1297-1303.
51. Kannan, R., Kuhlenkamp, J. F., Ookhtens, M., and Kaplowitz, N. (1992) Transport of glutathione at blood-brain barrier of the rat: Inhibition by glutathione analogs and age dependence. J. Pharmacol. Exp. Ther. 263, 964-970.
52. Hill, B. A., Lo, H.-H., Monks, T. J., and Lau, S. S. (1991) The role of γ-glutamyl transpeptidase in hydroquinone-glutathione conjugate mediated nephrotoxicity. Adv. Exp. Med. Biol. 283, 749-751.
53. Elce, J. S. (1972) Metabolism of a glutathione conjugate of 2-hydroxyoestradiol-17β in the adult male rat. Biochem. J 126, 1067-1071.
54. Rivera, M. I , Hinojosa, L. M., Hill, B. A., Lau, S. S., and Monks, T. J. (1994) Metabolism and toxicity of 2-bromo(diglutathion-S-yl)hydroquinone and 2-bromo-3-(glutathion-S-yl)hydroquinone in the in situ perfused rat kidney. Drug Metab. Dispos. 22, 503-510.
55. Hill, B. A., Davison, K. L., Dulik, D. M., Monks, T. J., and Lau, S. S. (1994) Metabolism of 2-(glutathion-S-yl)-hydroquinone and 2,3,5-(triglutathion-S-yl)hydroquinone in the in situ perfused rat kidney: Relationship to nephrotoxicity. Toxicol. Appl. Pharmacol. 129, 121-132.
56. Monks, T. J., Lo, H. H., and Lau, S. S. (1994) Oxidation and acetylation as determinants of 2-bromocystein-S-ylhydroquinone-mediated nephrotoxicity. Chem. Res Toxicol. 7, 495-502.